TARS
Tarsus
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
TARS Profile
Tarsus Pharmaceuticals, Inc.
A biopharmaceutical company that developing novel drugs used for the treatment of blepharitis
15440 Laguna Canyon Road, Suite 160, Irvine, California 92618
--
Tarsus Pharmaceuticals, Inc., was incorporated in November 2016 under the laws of the State of Delaware. The company is a late-stage clinical biopharmaceutical company dedicated to the development and commercialization of therapeutic drug candidates to address therapeutic options with limited initial market opportunities for ophthalmic diseases. The company's lead product candidate, TP-03, is a phase 2b/3 novel therapy currently under development for the treatment of blepharitis caused by Demodex, known as Demodex eye.